Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $472.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $472.3 million, up 37.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 27.09% YoY), and the FY2025 annual result was $485.6 million, up 37.1% from the prior year.
• Liabilities and Shareholders Equity eased to $472.3 million in Q1 2026 per TBPH's latest filing, from $485.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $763.5 million in Q3 2022 and troughed at $343.6 million in Q1 2025.
• A 5-year average of $438.5 million and a median of $413.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 89.4% in 2022, then sank 45.83% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $607.4 million in 2022, then plunged by 37.11% to $382.0 million in 2023, then dropped by 7.29% to $354.2 million in 2024, then soared by 37.1% to $485.6 million in 2025, then decreased by 2.73% to $472.3 million in 2026.
• Business Quant data shows TBPH's Liabilities and Shareholders Equity at $472.3 million in Q1 2026, $485.6 million in Q4 2025, and $415.5 million in Q3 2025.